SCHEMBL6749910

SCHEMBL6749910

COc1ccc(C(F)(F)c2ccc(OC(CCCNCC(=O)O)c3ccccc3)cc2)cc1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 3/20 0.46
SLC6A2 P23975 4/20 0.45
SLC6A4 P31645 4/20 0.45
SLC6A3 Q01959 4/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
LMNA P02545 4/20 0.45
NPC1 O15118 2/20 0.45
CYP2D6 P10635 2/20 0.45
CYP2C19 P33261 2/20 0.45
MTOR P42345 2/20 0.45
RAB9A P51151 2/20 0.45
CYP3A4 P08684 2/20 0.45
HTR2C P28335 2/20 0.45
KDM4E B2RXH2 1/20 0.45
TP53 P04637 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6753991 0.93 MAPT (0.44) SLC6A9SLC6A2SLC6A4SLC6A3MEN1
SCHEMBL6259766 0.90 SLC6A4 (0.50) SLC6A9SLC6A2SLC6A4SLC6A3MEN1
SCHEMBL6256212 0.89 SLC6A9 (0.46) SLC6A9SLC6A2SLC6A4SLC6A3MEN1
SCHEMBL6254431 0.88 SLC7A5 (0.51) SLC6A9SLC6A2SLC6A4SLC6A3MEN1
SCHEMBL6754006 0.88 SLC6A9 (0.44) SLC6A9SLC6A2SLC6A4SLC6A3MEN1
SCHEMBL6755046 0.88 SLC6A9 (0.46) SLC6A9SLC6A2SLC6A4SLC6A3MEN1
SCHEMBL6749875 0.86 SLC6A9 (0.50) SLC6A9SLC6A2SLC6A4SLC6A3MEN1
SCHEMBL6257279 0.86 SLC6A9 (0.50) SLC6A9SLC6A2SLC6A4SLC6A3MEN1
SCHEMBL6755047 0.86 SLC6A4 (0.50) SLC6A9SLC6A2SLC6A4SLC6A3MEN1
SCHEMBL6260298 0.86 SLC7A5 (0.47) SLC6A9SLC6A2SLC6A4SLC6A3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6710071-B2 SUCH AS ((3-4-(DIFLUORO(PHENYL)METHYL)PHENOXYL-3-PHENYLPROPYL)METHYLAMINO)ACETIC ACID; FOR THE ENHANCEMENT OF COGNITION AND THE TREATMENT OF SCIZOPHRENIA AND OTHER PSYCHOSES PFIZER INC 2004-03-23 US disclosed
US-20030045569-A1 Difluoromethylene aromatic ethers as inhibitors of glycine transport PFIZER INC. 2003-03-06 US disclosed
EP-1284257-A2 Difluoromethylene aromatic ethers and their use as inhibitors of the glycine type-1 transporter Pfizer Products Inc. (US) 2003-02-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045569-A1 Difluoromethylene aromatic ethers as inhibitors of glycine transport SLC1A2, SLC1A1, SLC1A3 SLC6A9 9/4885SLC6A2 20/4885SLC6A4 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.